A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

The expansion of the advanced therapy medicinal products market is primarily fueled by the increasing incidence of chronic diseases. The rising prevalence of genetic disorders and cancer, along ...

CRISPR technology, driven by Cas9, redefines gene editing, facilitating targeted DNA modifications that advance genetic ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

Researchers find a master epigenetic switch that activates silenced genes to compensate for their missing counterparts in a ...

周三（2月12日），投资者纷纷买入CRISPR Therapeutics（CRSP）股票，该股在交易时段结束时上涨超过9%。这家专业医疗公司周二盘后发布的最新季度财报让投资者大受鼓舞。这一超过9%的涨幅与标普500指数0.3%的跌幅形成鲜明对比。

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...